|Title:||Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a .beta.-adrenergic antagonist|
|Abstract:||Combinations of a .beta.-adrenergic antagonist and a topical carbonic anhydrase inhibitor are particularly useful in the treatment of ocular hypertension, especially in patients insufficiently responsive to treatment with .beta.-adrenergic antagonists.|
|Inventor(s):||Baldwin; John J. (Gwynedd Valley, PA)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Formulation; Compound;|
Field: Not categorized
Back Citations: 15th percentile
Forward Citations: 0th percentile
|Patent Number||Expiration Date|
|6,316,443||November 13, 2009|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.